[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"assisted-reproductive-techniques\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:assisted-reproductive-techniques":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,56,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":32,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100621860","effects-of-infertility-and-assisted-reproductive-technology-on-sexual-function-and-behavior-100621860",false,"NCT07376109","Effects of Infertility and Assisted Reproductive Technology on Sexual Function and Behavior","Effect of Infertility and Assisted Reproductive Technology (ART) on Sexual Function and Behaviour","Inclusion Criteria:\n\n1. Assigned female at birth.\n2. Self-identify as a woman.\n3. Age 18-44 years.\n4. Diagnosis of infertility.\n5. Seeking fertility treatment at the MUHC Reproductive Centre.\n\nExclusion Criteria:\n\n1. Assigned male at birth.\n2. Age 45 years or older.\n3. Sexual practices that do not allow for the possibility of conception (e.g., same-sex relationships without use of assisted reproductive technologies).\n4. Seeking oocyte cryopreservation.\n5. Individuals who do not wish to complete the anonymous questionnaire.","FEMALE","18 Years","44 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","This cross-sectional observational study examines how infertility and the use of assisted reproductive technology (ART) are related to sexual function and sexual behaviors in women seeking fertility treatment. Infertility and the stress of ART may be associated with changes in sexual desire, satisfaction, and activity. The purpose is to better understand these associations to support the sexual health and overall well-being of women undergoing fertility care.\n\nWomen who are assigned female at birth, under 45 years old, diagnosed with infertility, and attending appointments at the MUHC Reproductive Centre are invited to take part. Participants will be asked to complete an anonymous questionnaire while waiting for their clinical visit. The questionnaire includes the validated Female Sexual Function Index (FSFI), which measures different aspects of sexual function, and additional questions about sexual activities, such as frequency of intercourse and other behaviors before and after fertility treatments.\n\nParticipants will not provide any identifying information. Completed questionnaires will be placed in a secure collection box to protect confidentiality.\n\nData from approximately 500 participants will be analyzed to explore how infertility type (primary vs. secondary), duration of infertility, and the number of unsuccessful ART cycles relate to sexual function and behavior. Findings from this study may help healthcare providers better recognize and address the sexual health concerns of women with infertility.\n\nThis study is approved by the McGill University Health Centre Research Ethics Board (REB #2025-11459).",[25,26,27,28,29,30,31],"Infertility Assisted Reproductive Technology","Sexual Behavior","Sexual Function","Sexual Dysfunction and Infertility","Sexual Dysfunction Female","Infertility","Assisted Reproductive Techniques",[33,34,35,36,37,38,39,40,41,42],"infertility","Assisted Reproductive Technology","ART","IVF","female sexual function","female sexual function index","FSFI","sexual behavior","sexual dysfunction","women's sexual health","RECRUITING","2026-02-19",{"date":46,"type":47},"2026-02-20","ACTUAL",{"date":49,"type":47},"2026-02-06",{"date":51,"type":21},"2027-01",{"name":53,"class":54},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":72,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100619876","phase-4-trial-comparing-subcutaneous-natural-progesterone-prolutex-vs-cetrorelix-acetate-for-luteinizing-hormone-surge-suppression-in-freeze-all-ivf-cycles-100619876","NCT07350317","Trial Comparing Subcutaneous Natural Progesterone (Prolutex) vs. Cetrorelix Acetate for Luteinizing Hormone Surge Suppression in Freeze-All IVF Cycles.","A Non-Inferiority Randomized Controlled Trial Comparing Subcutaneous Natural Progesterone (Prolutex) vs. Cetrorelix Acetate for Luteinizing Hormone Surge Suppression in Freeze-All IVF Cycles.","IVF ART","Inclusion Criteria:\n\n1. Women aged 18-40 years.\n2. Body Mass Index \\\u003C 35 kg\u002Fm²\n3. Antral Follicle Count ≥ 8 or Anti-Müllerian Hormone ≥ 1.2 ng\u002FmL\n4. Undergoing freeze-all IVF (for Ovarian Hyperstimulation Syndrome - OHSS risk, PGT- Preimplantation Genetic Testing, or personal preference)\n\nExclusion Criteria:\n\n1. Poor responders (Bologna criteria)\n2. Stage III-IV endometriosis\n3. Pituitary or hypothalamic dysfunction\n4. Planned fresh embryo transfer\n5. Severe Male Factor. Semen Count \\\u003C1 ×〖10〗\\^6 (\\\u003C1 Million\u002Fml) or Azoospermia)","40 Years",{"count":66,"type":21},230,"INTERVENTIONAL",[69],"PHASE4","The prevention of premature luteinizing hormone (LH) surge during controlled ovarian stimulation (COS) is critical for optimizing outcomes in assisted reproductive technology (ART). Cetrorelix acetate, a GnRH (Gonadotropin releasing hormone) antagonist administered subcutaneously, is the current standard for luteinizing hormone suppression. However, natural progesterone in a novel subcutaneous formulation (Prolutex) may offer a viable alternative.\n\nProlutex is a water-soluble complex of natural progesterone with hydroxypropyl-β-cyclodextrin (HPBCD), patented as US Patent No. 4,727,064 Pitha, Jallowing for subcutaneous injection. This may simplify treatment and improve patient compliance.\n\nProgesterone forms are well studied and used globally\u002Fin UAE to suppress Luteinizing Hormone surge. It is an example of off-label use, which becomes a standard indication for use of progesterone. Several studies have demonstrated that exogenous progesterone can effectively suppress Luteinizing Hormone release while maintaining follicular development and oocyte competence. Furthermore, progestin-based protocols are potentially more cost-effective and similar to administer compared to GnRH (Gonadotropin releasing hormone) antagonists.\n\nTo our knowledge, this is the first randomized trial directly comparing a subcutaneous progesterone formulation (Prolutex) with cetrorelix acetate, administered via the same route, in terms of luteinizing hormone surge suppression. For this specific research, there are no relevant published studies available. This Randomised controlled trial will be done to address the research gap and compare the two already approved standard of care medications to see if Prolutex can be used as a viable alternative to suppress Luteinizing Hormone levels.",[31],[73,74,75],"ivf protocol","prolutex","premature ovulation","NOT_YET_RECRUITING","2026-01-13",{"date":79,"type":47},"2026-01-20",{"date":81,"type":21},"2026-01",{"date":83,"type":21},"2027-02",{"name":85,"class":54},"Trust Fertility Clinic",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":67,"phases":97,"briefSummary":99,"conditions":100,"keywords":105,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":5},"100573090","direct-warming-frozen-embryo-transfer-outcomes-in-assisted-reproductive-technology-100573090","NCT06741748","Direct Warming Frozen Embryo Transfer Outcomes in Assisted Reproductive Technology","A Pragmatic, Multi-centre, Double-blinded, Two-arm Randomized Controlled Trial on a Direct Warming Frozen Embryo Transfer in Assisted Reproductive Technologies Treatment Outcome","DW-FET-RCT","Inclusion Criteria:\n\n* Plan to undergo single embryo transfer (SET) during the FET cycle.\n* Age between 18 and 45 years.\n* Patients with at least one high-quality blastocyst available for transfer.\n* Patients who have provided informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with repeated implantation failure (RIF) or recurrent miscarriage (RM).\n* Patients with known uterine anomalies or significant uterine pathology (e.g., fibroids, polyps).\n* Patients who are unwilling or unable to provide informed consent.","45 Years",{"count":96,"type":21},578,[98],"NA","The goal of this clinical trial is to evaluate whether the direct warming method for frozen embryo transfers (FET) can improve live birth and pregnancy outcomes in women aged 18-45 undergoing IVF treatments. The main questions it aims to answer are:\n\n* Does the direct warming method achieve a similar or higher clinical success rate for FET compared to the conventional multi-step method?\n* Is the direct warming method more cost-effective than the conventional method?\n\nResearchers will compare the direct warming method to the conventional multi-step method to see if the former leads to better pregnancy outcomes and reduced procedural time.\n\nParticipants will:\n\n* Undergo either the one-step or conventional embryo thawing procedure.\n* Complete standard clinical follow-ups for pregnancy, including ultrasound scans and pregnancy tests.",[101,31,102,103,104],"Frozen Embryo Transfer (FET)","In Vitro Fertilization (IVF)","Cryopreservation of Embryos","Pregnancy Outcome After in Vitro Fertilization (IVF)",[106,107,108,109,110,111,112],"Direct Warming Method","Frozen Embryo Transfer","Assisted Reproductive Technologies","Cryopreservation","Cost-effectiveness in ART","Embryo Warming","In Vitro Fertilization","2025-03-06",{"date":115,"type":47},"2025-03-11",{"date":117,"type":21},"2025-09-01",{"date":119,"type":21},"2027-10-31",{"name":121,"class":54},"Chinese University of Hong Kong"]